Floatz logo

Milademetan

CDKN2A

Rain Oncology IncPhase 1/2Active
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the CDKN2A cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Rain Oncology Inc
Phase 1/2CCC
Atezolizumab
Rain Oncology Inc
Phase 1/2CCC

Same molecule, other indications

Milademetan is also rated in:

breast cancerDormant
C
Indicative ·
36 / 100
View asset →
cancerDormant
C
Indicative ·
34 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →